The effect of methylphenidate for giggle incontinence in children
© 2023 The Authors. Neurourology and Urodynamics published by Wiley Periodicals LLC..
INTRODUCTION: Giggle incontinence (GI) is a rare form of urinary incontinence that occurs during or immediately after laughing due to involuntary and complete bladder emptying. Few studies in the literature report that methylphenidate can be effective in treatment of this condition.
OBJECTIVE: The aim of this study is to characterize children with GI and evaluate their response to methylphenidate, as well as describe treatment duration, dosage of methylphenidate, relapse rates after discontinuation of medication, and side effects.
METHODS: Medical records and 48-h frequency-volume charts from children treated with methylphenidate for GI in the period January 2011-July 2021 were retrospectively analyzed.
RESULTS: Eighteen children were diagnosed with GI and fulfilled inclusion criteria. Fifteen patients were included in analysis, as 3 out of 18 children decided not to take the methylphenidate that was prescribed. In total, 14 out of the 15 GI patients treated with methylphenidate experienced clinical effect. All patients included in the study had methylphenidate prescribed in a dose range of 5-20 mg daily. Treatment duration ranged from 30 to 1001 days, with a median of 152 days (IQR 114, 243.5). Ten children experienced complete response and two of those reported symptom relapse after discontinuation of the methylphenidate. Only mild and short-lasting side effects were reported by two patients.
DISCUSSION: Our study demonstrates that methylphenidate is an effective treatment in children diagnosed with GI. Side effects are mild and uncommon.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:42 |
|---|---|
| Enthalten in: |
Neurourology and urodynamics - 42(2023), 7 vom: 12. Sept., Seite 1470-1475 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Svendsen, Ann-Kristine Mandoe [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
207ZZ9QZ49 |
|---|
| Anmerkungen: |
Date Completed 17.08.2023 Date Revised 19.08.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1002/nau.25232 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM358781515 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM358781515 | ||
| 003 | DE-627 | ||
| 005 | 20231226075452.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231226s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1002/nau.25232 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1195.xml |
| 035 | |a (DE-627)NLM358781515 | ||
| 035 | |a (NLM)37376840 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Svendsen, Ann-Kristine Mandoe |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The effect of methylphenidate for giggle incontinence in children |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 17.08.2023 | ||
| 500 | |a Date Revised 19.08.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2023 The Authors. Neurourology and Urodynamics published by Wiley Periodicals LLC. | ||
| 520 | |a INTRODUCTION: Giggle incontinence (GI) is a rare form of urinary incontinence that occurs during or immediately after laughing due to involuntary and complete bladder emptying. Few studies in the literature report that methylphenidate can be effective in treatment of this condition | ||
| 520 | |a OBJECTIVE: The aim of this study is to characterize children with GI and evaluate their response to methylphenidate, as well as describe treatment duration, dosage of methylphenidate, relapse rates after discontinuation of medication, and side effects | ||
| 520 | |a METHODS: Medical records and 48-h frequency-volume charts from children treated with methylphenidate for GI in the period January 2011-July 2021 were retrospectively analyzed | ||
| 520 | |a RESULTS: Eighteen children were diagnosed with GI and fulfilled inclusion criteria. Fifteen patients were included in analysis, as 3 out of 18 children decided not to take the methylphenidate that was prescribed. In total, 14 out of the 15 GI patients treated with methylphenidate experienced clinical effect. All patients included in the study had methylphenidate prescribed in a dose range of 5-20 mg daily. Treatment duration ranged from 30 to 1001 days, with a median of 152 days (IQR 114, 243.5). Ten children experienced complete response and two of those reported symptom relapse after discontinuation of the methylphenidate. Only mild and short-lasting side effects were reported by two patients | ||
| 520 | |a DISCUSSION: Our study demonstrates that methylphenidate is an effective treatment in children diagnosed with GI. Side effects are mild and uncommon | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a enuresis risoria | |
| 650 | 4 | |a giggle incontinence | |
| 650 | 4 | |a methylphenidate | |
| 650 | 4 | |a urinary incontinence | |
| 650 | 7 | |a Methylphenidate |2 NLM | |
| 650 | 7 | |a 207ZZ9QZ49 |2 NLM | |
| 700 | 1 | |a Kamperis, Konstantinos |e verfasserin |4 aut | |
| 700 | 1 | |a Hagstroem, Soeren |e verfasserin |4 aut | |
| 700 | 1 | |a Thorsteinsson, Kristina Nauheimer |e verfasserin |4 aut | |
| 700 | 1 | |a Arvad, Mads |e verfasserin |4 aut | |
| 700 | 1 | |a Borch, Luise |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Neurourology and urodynamics |d 1993 |g 42(2023), 7 vom: 12. Sept., Seite 1470-1475 |w (DE-627)NLM074810308 |x 1520-6777 |7 nnns |
| 773 | 1 | 8 | |g volume:42 |g year:2023 |g number:7 |g day:12 |g month:09 |g pages:1470-1475 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1002/nau.25232 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 42 |j 2023 |e 7 |b 12 |c 09 |h 1470-1475 | ||